Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot placebo-controlled trial

OBJECTIVE: Obsessive-compulsive disorder (OCD) affects approximately 2.5% of the population and is associated with significant morbidity. Many patients receive little benefit from the best available treatments, and even those who do respond often suffer from significant residual symptoms. Convergent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Psychiatry
Autors principals: Pittenger, Christopher, Bloch, Michael H., Wasylink, Suzanne, Billingslea, Eileen, Simpson, Ryan, Jakubovski, Ewgeni, Kelmendi, Ben, Sanacora, Gerard, Coric, Vladimir
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560666/
https://ncbi.nlm.nih.gov/pubmed/26214725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/JCP.14m09123
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars